TAK-788; AP32788 MedChemExpress (MCE)

Product Name	TAK-788
Synonyms	TAK-788 AP32788 AP 32788 Mobocertinib Mobocertinib (TAK788) AP32788, MOBOCERTINIB Mobocertinib (TAK788, AP32788) Synonyms TAK-788 AP32788 AP 32788 Mobocertinib Mobocertinib (TAK788) AP32788, MOBOCERTINIB Mobocertinib (TAK788, AP32788) Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate 5-Pyrimidinecarboxylic acid, 2-[[4-[[2-(dimethylamino)ethyl]methylamino]-2-methoxy-5-[(1-oxo-2-propen-1-yl)amino]phenyl]amino]-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester
CAS	1847461-43-1
EINECS
Chemical Formula	C₃₂H₃₉N₇O₄
Molecular Weight	585.70
inchi
Package	10 mM * 1 mL;1 mg;5 mg;10 mg;25 mg;50 mg;100 mg;500 mg
Price	Email to quote
Descriptions	Mobocertinib Mobocertinib MedChemExpress (MCE) HY-135815 1847461-43-1 TAK-788 Descriptions Mobocertinib Mobocertinib MedChemExpress (MCE) HY-135815 1847461-43-1 TAK-788 AP32788 99.60% Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year Room temperature in continental US may vary elsewhere. Mobocertinib (TAK-788) is an orally active and irreversible EGFR/HER2 inhibitor. Mobocertinib potently inhibits oncogenic variants containing activating EGFRex20ins mutations with selectivity over wild-type EGFR. Mobocertinib can be used in NSCLC research. Mobocertinib (1.5 nM-10 μM 7 days) inhibits LU0387 (NPH) cells with IC50 of 21 nM[1]. Mobocertinib (2 h) potently inhibits EGFR with common activating mutations (HCC827 (D), HCC4011 (L)) or with a T790M mutation (H1975 (LT)) more potently than WT EGFR (A431 (WT))[1]. Mobocertinib (0.1 nM-1 μM 6 h) inhibits pEGFR and pERK1/2 in CUTO14 (ASV) cells[1]. Mobocertinib (0.3 nM-1 μM 6 h) inhibits EGFR and downstream signaling[1]. Mobocertinib (0.01, 0.1 and 1 μM 6 h) inhibits HER2 signaling in H1781 (HER2 Exon 20G776>VC), Ba/F3 (HER2 exon 20YVMA) cells[2]. Mobocertinib (3, 10, 30 mg/kg p.o. once daily for 20 days) significantly induces tumor growth inhibition[1]. EGFR (WT) EGFR exon 20 insertion HER2 \| \| \| \| \| \| \| \| \| \| [1]. Gonzalvez F, et al. Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer. Cancer Discov. 2021 Jul 11(7):1672-1687. [Content Brief] [2]. Han H, et al. Targeting HER2 Exon 20 Insertion-Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor Mobocertinib. Cancer Res. 2021 Oct 15 81(20):5311-5324. [Content Brief]
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Thalidomide-4-O-C2-NH2

Category: Signaling Pathways
CAS: 2341840-99-9
Last Update: 2025-04-01 14:45:47

PPARα-MO-1

Category: Signaling Pathways
CAS: 810677-36-2
Last Update: 2025-04-01 14:45:47

Netupitant N-oxide

Category: Signaling Pathways
CAS: 910808-11-6
Last Update: 2025-04-01 14:45:47

MK-0812

Category: Signaling Pathways
CAS: 624733-88-6
Last Update: 2025-04-01 14:45:47

TS-011

Category: Signaling Pathways
CAS: 339071-18-0
Last Update: 2025-04-01 14:45:47

SCH 530348 sulfate

Category: Signaling Pathways
CAS: 705260-08-8
Last Update: 2025-04-01 14:45:47

BAG 956

Category: Signaling Pathways
CAS: 853910-02-8
Last Update: 2025-04-01 14:45:47

YM758

Category: Signaling Pathways
CAS: 312752-85-5
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact